Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
2.430
-0.060 (-2.41%)
May 1, 2025, 4:00 PM EDT - Market closed
Alto Neuroscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
76
Market Cap
65.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 210.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionANRO News
- 3 days ago - Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach - Business Wire
- 9 days ago - Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day - Business Wire
- 6 weeks ago - Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Business Wire
- 2 months ago - The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation - Accesswire
- 2 months ago - Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker - Business Wire
- 2 months ago - Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial - Business Wire
- 3 months ago - The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud - Accesswire